Your response was submitted successfully!

Thank you for your interest in Airfinity.

Stay up to date with the latest insights, news and product releases by following us on social media.

Airfinity background image landing page

Analysis & Insights

Watch our on demand webinar on: Weight of the world: are anti-obesity therapeutics transforming the global health landscape for good

More from Airfinity

Wegovy costs $1.3m to prevent one heart attack, stroke, or cardiovascular death

Anti-obesity drug rush: Industry 'testing' nearly 190 candidates (es)

Weight loss injections could prevent 300,000 heart failures in the US by 2030, forecasts Airfinity

Airfinity forecasts the severely obese population with metabolic syndrome in the US to grow 50% by 2030 from 26 million to 39.1 million people.

View All →

astra

In a dynamic environment, Airfinity enabled us to remain on track with daily developments to enable more accurate decision-making. Airfinity combines nimbleness of real time data and their group of scientists that can analyse, model and provide strategic analysis for critical decision making.”

Iskra Reic, Executive Vice-President
Astrazeneca

geovax

“Airfinity is a true partner in pushing the absolutely critical work we do to advance vaccines into the clinical space. Their team provides exceptional collaboration and intelligent data analytics that support our organisation in business and scientific decision making in a challenging, rapidly evolving emerging disease field.”

GeoVax

Oxford

“Vaccine production data from Airfinity has been spot on. In a fast moving pandemic, these forecasts are important for evidence–based policy making.”

Director General ,
IFPMA